The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

The leaked budget draft, if approved by Congress, would reduce the FDA’s budget authority, indicating more disruption could ...